KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Shares Issued (2020 - 2025)

Recursion Pharmaceuticals' Shares Issued history spans 6 years, with the latest figure at $793000.0 for Q4 2025.

  • For Q4 2025, Shares Issued fell 99.73% year-over-year to $793000.0; the TTM value through Dec 2025 reached $4.1 million, down 98.64%, while the annual FY2025 figure was $4.1 million, 98.64% down from the prior year.
  • Shares Issued reached $793000.0 in Q4 2025 per RXRX's latest filing, up from -$993000.0 in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $460.7 million in Q2 2021 to a low of -$458.3 million in Q3 2021.
  • Average Shares Issued over 5 years is $18.7 million, with a median of $2.1 million recorded in 2021.
  • The largest YoY upside for Shares Issued was 2879768.75% in 2021 against a maximum downside of 201985.9% in 2021.
  • A 5-year view of Shares Issued shows it stood at $3.8 million in 2021, then soared by 180.95% to $10.7 million in 2022, then crashed by 446.83% to -$37.2 million in 2023, then surged by 890.41% to $294.0 million in 2024, then plummeted by 99.73% to $793000.0 in 2025.
  • Per Business Quant, the three most recent readings for RXRX's Shares Issued are $793000.0 (Q4 2025), -$993000.0 (Q3 2025), and $2.7 million (Q2 2025).